pioglitazone has been researched along with Soft Tissue Neoplasms in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, thyroid cancers that are progressive despite standard-of-care therapy appear to only rarely express PPFP." | 2.87 | Pioglitazone Therapy of PAX8-PPARĪ³ Fusion Protein Thyroid Carcinoma. ( Caoili, EM; Giordano, TJ; Haugen, BR; Koenig, RJ; Shah, MH; Sherman, SI, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giordano, TJ | 1 |
| Haugen, BR | 1 |
| Sherman, SI | 1 |
| Shah, MH | 1 |
| Caoili, EM | 1 |
| Koenig, RJ | 1 |
| Kasper, B | 1 |
| Ho, AD | 1 |
| Egerer, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene[NCT01655719] | Phase 2 | 1 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Toxicities experienced by patients with PAX8-PPARgamma fusion gene-positive follicular-patterned thyroid carcinomas treated with pioglitazone are indicated by presence of Serious Adverse Events (that show relatedness). (NCT01655719)
Timeframe: 24 weeks
| Intervention | serious adverse events (Number) |
|---|---|
| Pioglitazone Treatment | 0 |
Determine if pioglitazone decreases serum thyroglobulin in patients with follicular-patterned thyroid carcinomas that contain the PAX8-PPARgamma fusion gene. (NCT01655719)
Timeframe: Baseline and 24 weeks
| Intervention | ng/mL (Number) | |
|---|---|---|
| Baseline | 24 weeks | |
| Pioglitazone Treatment | 1974 | 49.4 |
Response is measured by change in Tumor size (cm) (NCT01655719)
Timeframe: Baseline and 24 weeks
| Intervention | cm (Number) | |
|---|---|---|
| Baseline | 24 weeks | |
| Pioglitazone Treatment | 6.0 | 3.9 |
1 trial available for pioglitazone and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Pioglitazone Therapy of PAX8-PPARĪ³ Fusion Protein Thyroid Carcinoma.
Topics: Adenoma, Oxyphilic; Aged, 80 and over; Antineoplastic Agents; Humans; Male; Mutation; Oncogene Prote | 2018 |
1 other study available for pioglitazone and Soft Tissue Neoplasms
| Article | Year |
|---|---|
A new therapeutic approach in patients with advanced sarcoma.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cycl | 2005 |